Is Journey Medical Corporation Common Stock a good investment? Journey Medical Corporation Common Stock (DERM) is currently trading at 6.63 USD. Market analysts have a consensus price target of 13.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: Journey Medical Corporation Common Stock is expected to release its next earnings report on May 19, 2026. The market consensus estimate for Forward EPS is -0.06.
No, it does not currently pay a dividend.
Journey Medical Corporation Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be May 19, 2026. The company currently has a trailing EPS of -0.37.
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion